KURA vs. PTGX, VERA, CGON, HRMY, MIRM, BEAM, CNTA, MESO, IDYA, and AGIO
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), CG Oncology (CGON), Harmony Biosciences (HRMY), Mirum Pharmaceuticals (MIRM), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Mesoblast (MESO), IDEAYA Biosciences (IDYA), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry.
Kura Oncology vs.
Kura Oncology (NASDAQ:KURA) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends.
Protagonist Therapeutics has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Protagonist Therapeutics has a net margin of 52.76% compared to Kura Oncology's net margin of 0.00%. Protagonist Therapeutics' return on equity of 34.68% beat Kura Oncology's return on equity.
In the previous week, Protagonist Therapeutics had 3 more articles in the media than Kura Oncology. MarketBeat recorded 6 mentions for Protagonist Therapeutics and 3 mentions for Kura Oncology. Protagonist Therapeutics' average media sentiment score of 0.69 beat Kura Oncology's score of 0.10 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Kura Oncology has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.
Kura Oncology received 147 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 69.44% of users gave Kura Oncology an outperform vote while only 60.83% of users gave Protagonist Therapeutics an outperform vote.
98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.5% of Kura Oncology shares are held by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Kura Oncology currently has a consensus target price of $27.38, suggesting a potential upside of 277.07%. Protagonist Therapeutics has a consensus target price of $53.78, suggesting a potential upside of 46.06%. Given Kura Oncology's higher possible upside, analysts plainly believe Kura Oncology is more favorable than Protagonist Therapeutics.
Summary
Protagonist Therapeutics beats Kura Oncology on 12 of the 17 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:KURA) was last updated on 1/18/2025 by MarketBeat.com Staff
Free KURA Stock Alerts